Frontlight ResearchEarly access
Active, not recruitingPhase 1
Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress Disorder
Key facts
- Who runs it
- Yale University
- Where
- New Haven, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 25 people, planned
- Started
- 1 Aug 2023
- Ended
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Brexanolone
- Record updated
- 14 October 2025
Who can take part
- Age
- 21 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 21-55 years old
- Meet DSM-5 diagnostic criteria for AUD within the past 6 months, as well as the following drinking criteria:; Men: drink greater than 14 drinks per week and exceed five drinks per day at least once per week within the past 30 days; Women: drink greater than 7 drinks per week and exceed four drinks per day at least once per week within the past 30 days
- Meet DSM-5 diagnostic criteria for PTSD in the past 6 months
Who cannot take part
- Past 30 day use of psychoactive drugs including anxiolytics and antidepressants
- Women who are pregnant or nursing, or fail to use one of the following methods of birth control unless she or her partner is surgically sterile or she is postmenopausal (hormone contraceptives [oral, implant, injection, patch, or ring], contraceptive sponge, double barrier [diaphragm or condom plus spermicide], or IUD)
- Specific exclusions for the administration of brexanolone not already specified include: Individuals with end stage renal disease, treatment with any opioids or other CNS depressants, such as benzodiazepines
- Likely to experience clinically significant alcohol withdrawal during the study procedures (e.g., history of alcohol-related perceptual distortions/hallucinations, seizures, or Clinical Institute Withdrawal Assessment Scale score > 8 at intake)
- Meets DSM-5 diagnostic criteria for schizophrenia, bipolar disorder, and/or other severe mental illnesses
- Meets criteria for current (past 6 months) substance use disorders (other than tobacco use disorder)
- Any significant current medical conditions (neurological, cardiovascular [including hypertension or hypotension: sitting BP >160/100 or <90/60mmHg at baseline screening], endocrine, thyroid, renal, liver), seizures, delirium or hallucinations, or other unstable medical conditions including HIV
- Subjects likely to exhibit clinically significant alcohol withdrawal during the study. Specifically, we will exclude subjects who a) have a history of perceptual distortions, seizures, delirium, or hallucinations upon withdrawal or b) have a score of > 8 on the Clinical Institute Withdrawal Assessment scale at intake appointments
- Actively seeking treatment for AUD
- Current (i.e., past month) active suicidal ideation and/or homicidal ideation
- Tests positive for illicit substances during urine toxicology screens (except cannabis) at intake session
- Is actively engaged in psychotherapy to treat PTSD
- Participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current application
Where in United States
- Yale School of MedicineNew Haven, United States
About the trial
What the trial wants to find out
For this protocol, the investigators plan to collect pilot data to: 1. establish the feasibility and safety of administering brexanolone to individuals with concurrent Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD).
The group in the trial
- BrexanaoloneTreatment being tested
In this single-arm study, participants will be administered brexanolone as a continuous IV infusion over 20 hours (titrated up to 90mcg/kg/hour).
Treatment: Brexanolone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 14 October 2025